S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
NASDAQ:CSTL

Castle Biosciences - CSTL Stock Forecast, Price & News

$24.60
+0.92 (+3.89%)
(As of 12/8/2022 02:25 PM ET)
Add
Compare
Today's Range
$23.45
▼
$24.86
50-Day Range
$18.08
▼
$30.00
52-Week Range
$15.58
▼
$48.40
Volume
2,443 shs
Average Volume
205,813 shs
Market Capitalization
$648.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.86

Castle Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.6% Upside
$57.86 Price Target
Short Interest
Healthy
4.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Castle Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$605,791 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.02) to ($2.98) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

163rd out of 1,027 stocks

Medical Laboratories Industry

7th out of 24 stocks

See Top Rated MarketRank™ Stocks Here
CSTL stock logo

About Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Stock News Headlines

December 3, 2022 | americanbankingnews.com
Insider Buying: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Purchases 1,162 Shares of Stock
December 1, 2022 | americanbankingnews.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Up 8.1%
November 22, 2022 | bizjournals.com
Pittsburgh lab receives pathology certification
November 21, 2022 | finance.yahoo.com
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
November 17, 2022 | finance.yahoo.com
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
November 15, 2022 | finance.yahoo.com
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
November 14, 2022 | finance.yahoo.com
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
November 3, 2022 | finance.yahoo.com
Increasing losses over year doesn't faze Castle Biosciences (NASDAQ:CSTL) investors as stock jumps 11% this past week
November 3, 2022 | seekingalpha.com
Castle Biosciences, Inc. (CSTL) Q3 2022 Earnings Call Transcript
November 2, 2022 | finance.yahoo.com
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates
November 2, 2022 | finance.yahoo.com
Castle Biosciences Announces Third Quarter 2022 Results
October 31, 2022 | finance.yahoo.com
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
October 27, 2022 | finance.yahoo.com
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
October 25, 2022 | seekingalpha.com
Castle Biosciences rises on new data for TissueCypher esophageal cancer test
October 25, 2022 | finance.yahoo.com
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
October 24, 2022 | finance.yahoo.com
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
October 20, 2022 | finance.yahoo.com
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
October 19, 2022 | finance.yahoo.com
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
October 15, 2022 | morningstar.com
Castle Biosciences Inc CSTL Stock Quote
October 15, 2022 | uk.finance.yahoo.com
Castle Biosciences, Inc. (CSTL)
October 13, 2022 | finance.yahoo.com
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
October 12, 2022 | finance.yahoo.com
Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic
October 11, 2022 | finance.yahoo.com
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
October 10, 2022 | finance.yahoo.com
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
September 23, 2022 | markets.businessinsider.com
BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Company Calendar

Last Earnings
11/07/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CSTL
CUSIP
N/A
CIK
1447362
Web
castlebiosciences.com
Phone
(866) 788-9007
Fax
N/A
Employees
342
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.86
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$41.00
Forecasted Upside/Downside
+135.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,290,000.00
Net Margins
-42.79%
Pretax Margin
-51.32%
Return on Equity
-11.87%
Return on Assets
-10.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.37
Quick Ratio
9.25

Sales & Book Value

Annual Sales
$94.08 million
Price / Sales
6.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.27 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
26,350,000
Free Float
24,428,000
Market Cap
$648.21 million
Optionable
Not Optionable
Beta
1.03

Key Executives

  • Mr. Derek J. MaetzoldMr. Derek J. Maetzold (Age 60)
    Founder, CEO, Pres & Director
    Comp: $1.36M
  • Mr. Frank StokesMr. Frank Stokes (Age 52)
    CFO & Treasurer
    Comp: $803.01k
  • Ms. Kristen M. Oelschlager R.N.Ms. Kristen M. Oelschlager R.N. (Age 54)
    RN, Chief Operating Officer
    Comp: $724.6k
  • Mr. Toby W. Juvenal (Age 61)
    Chief Commercial Officer
    Comp: $724.6k
  • Camilla Zuckero
    Exec. Director of Investor Relations & Corp. Communications
  • Ms. Alice Bahner Izzo
    Sr. VP of Marketing
  • Ms. Keli Greenberg
    VP of HR & Exec. Director of HR
  • Dr. Robert W. Cook Ph.D. (Age 50)
    Sr. VP of R&D
  • Mr. Bernhard E. SpiessMr. Bernhard E. Spiess (Age 62)
    Company Sec.
  • Mr. John W. Abbott
    VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CSTL Stock - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.

What is Castle Biosciences' stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $41.00 to $80.00. On average, they expect the company's stock price to reach $57.86 in the next year. This suggests a possible upside of 144.3% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2022?

Castle Biosciences' stock was trading at $42.87 at the beginning of 2022. Since then, CSTL stock has decreased by 44.8% and is now trading at $23.68.
View the best growth stocks for 2022 here.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,060,000 shares, a decrease of 9.4% from the October 31st total of 1,170,000 shares. Based on an average daily volume of 200,400 shares, the short-interest ratio is currently 5.3 days. Approximately 4.3% of the shares of the company are short sold.
View Castle Biosciences' Short Interest.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our CSTL earnings forecast.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The company earned $23.48 million during the quarter, compared to analysts' expectations of $23.66 million. Castle Biosciences had a negative trailing twelve-month return on equity of 11.87% and a negative net margin of 42.79%. During the same period in the previous year, the firm earned ($0.23) earnings per share.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132.00 million-$137.00 million, compared to the consensus revenue estimate of $132.25 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.75%), Vanguard Group Inc. (4.75%), Bellevue Group AG (3.57%), Kornitzer Capital Management Inc. KS (2.37%), Palisade Capital Management LLC NJ (2.20%) and RTW Investments LP (1.96%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Sofinnova Healthquest Partners, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $23.68.

How much money does Castle Biosciences make?

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $624.02 million and generates $94.08 million in revenue each year. The company earns $-31,290,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Castle Biosciences have?

The company employs 342 workers across the globe.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.

This page (NASDAQ:CSTL) was last updated on 12/8/2022 by MarketBeat.com Staff